The Tecan Group (SIX Swiss Exchange: TECN) today announced that the sale of REMP AG, a wholly owned subsidiary of Tecan, as well as other related assets, to NEXUS Biosystems has been completed as planned. From September 1, 2010, the Sample Management business segment will no longer be consolidated within the Tecan Group. It will be presented in the 2010 financial statements as a discontinued operation.

Tecan announced on July 15, 2010 that it would sell all the activities of the Sample Management business segment to NEXUS as part of its strategic portfolio alignment. Tecan will now focus its resources on growth projects in its core business and actively expand both its end-customer business and its OEM activities.

About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics. The company specializes in the development, production and distribution of instruments and automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer, Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2009, Tecan generated sales of CHF 392 million (USD 361.2 million; EUR 259.6 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN CH0012100191).